フェルナンドア・アデノフィラ (Wall. アルツハイマー病の治療のための多標的コレステラス阻害剤としてのG.Don) steenis,その後の分子ドッキング研究
Maria1, Asifullah Khan1, Rahaf Ajaj2
1Department of Biochemistry, Abdul Wali Khan University, Mardan, Khyber Pakhtunkhwa, Pakistan.
PloS one
|September 5, 2025
まとめ
フェルナンドア・アデノフィラ (Fernandoa adenophylla) の植物化学物質は,アセチルコレネステラーゼ (AChE) とブチリコレネステラーゼ (BuChE) を阻害することで,アルツハイマー病の治療に有望である. これらの化合物は アルツハイマー病の新たな治療法を 開発する可能性を秘めています
科学分野:
- 薬剤化学
- 神経科学
- 薬理学について
背景:
- アルツハイマー病 (AD) は認知機能に影響を与える進行性神経変性疾患です.
- アセチルコリネステラゼ (AChE) とブチリルコリネステラゼ (BuChE) は,ADの治療における重要な標的である.
研究 の 目的:
- フェルナンドア・アデノフィラ菌の化合物のコレネステラゼ阻害力を分離し,特徴づけ,評価する.
- 潜在的AD治療薬として,有意なAChEおよびBuChE抑制活性を持つ新しい植物化学物質を特定する.
主な方法:
- コリンエステラスの抑制作用を評価するために,インビトロ酵素阻害アッセイを使用した.
- フィトケミカルがフェルナンドア・アデノフィラから分離され,特徴づけられた.
- 酵素阻害剤の相互作用を理解するために分子ドッキング試験が行われました.
主要な成果:
- ラパコル,α-ラパホン,ペシャワラキノン,デヒドロ-α-ラパホン,インダノンの誘導体を含む5つの生物活性化合物が特定されました.
- ペシャワラキノンはAChE (IC50 = 0. 90 μM) と BuChE (IC50 = 8. 39 μM) の両方を強力に抑制した.
- デヒドロα- ラパホンは選択的なACHE阻害を示した (SI=21. 1).
結論:
- フェルナンドア・アデノフィラから得られた化合物は,コリネステラスを抑制する有意な潜在能力を有する.
- ペシャワラキノンとデヒドロ-α-ラパホンは,アルツハイマー病の治療薬としてさらなる開発に有望な候補である.
- これらの発見は,神経変性疾患に対するF.アデノフィラ由来植物化学物の治療可能性を強調しています.
さらに関連する動画
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.6K
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.5K
関連する概念動画
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
645
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
645
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
820
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
820
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
1.2K